Journal
PHARMACEUTICALS
Volume 15, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/ph15010013
Keywords
theranostics; tumor; gene therapy; cell-based therapy; molecular imaging; positron emission tomography; radiopharmaceuticals
Categories
Funding
- Horizon 2020 Programme [675417]
- Herbert-Worch-Stiftung
- Collaboration Grant of the Medical Faculty of the University of Bonn
- [831514]
Ask authors/readers for more resources
Radioligand theranostics in oncology utilize cancer-type specific biomarkers and molecular imaging for patient diagnosis, therapy, and personalized management. The concept has evolved with the development of theranostic pairs and the combination of nuclear medicine with different types of cancer therapies. The clinical applications of different theranostic radiopharmaceuticals in managing different tumor types support the combination of innovative oncological therapies such as gene and cell-based therapies with RT.
Radioligand theranostics (RT) in oncology use cancer-type specific biomarkers and molecular imaging (MI), including positron emission tomography (PET), single-photon emission computed tomography (SPECT) and planar scintigraphy, for patient diagnosis, therapy, and personalized management. While the definition of theranostics was initially restricted to a single compound allowing visualization and therapy simultaneously, the concept has been widened with the development of theranostic pairs and the combination of nuclear medicine with different types of cancer therapies. Here, we review the clinical applications of different theranostic radiopharmaceuticals in managing different tumor types (differentiated thyroid, neuroendocrine prostate, and breast cancer) that support the combination of innovative oncological therapies such as gene and cell-based therapies with RT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available